Evidence map›Paper›PMID 38057270›Full record

ArticleJournal of Zhejiang University. Science. B2023

A case of vitiligo after COVID-19 vaccination: a possible role of thymic dysfunction.

Denis Kuznetsov, Oleg Kalyuzhin, Andrey Mironov, Valery Neschisliaev, Anastasiia Kuznetsova

Abstract readCase Reports
In one paragraph

Article in Journal of Zhejiang University. Science. B, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Denis KuznetsovG N. Gabrichevsky Scientific and Research Institute of Epidemiology and Microbiology, Moscow 125212, Russia. denis.pfa@gmail.com.
Oleg KalyuzhinI M. Sechenov First Moscow State Medical University, Moscow 119991, Russia.
Andrey MironovG N. Gabrichevsky Scientific and Research Institute of Epidemiology and Microbiology, Moscow 125212, Russia.
Valery NeschisliaevPerm State Pharmaceutical Academy, Perm 614990, Russia.
Anastasiia KuznetsovaPerm State Pharmaceutical Academy, Perm 614990, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During the coronavirus disease 2019 (COVID-19) pandemic, vaccines help control the spread of infection. To date, 47 vaccines have been approved, with another 227 candidates in various stages of development. In the short period of time since the beginning of their use, evidence has begun to emerge of complications following vaccination in the form of the development or exacerbation of a number of pathological conditions (Block et al., 2022; Haseeb et al., 2022). For example, a population-based study in France identified 1612 cases of myocarditis and 1613 cases of pericarditis requiring hospital treatment within five months of vaccination (le Vu et al., 2022).

Indexed as

COVID-19COVID-19 VaccinesVitiligoHumansThymus GlandVaccinationCOVID-19 Vaccines

Identifiers

PMID38057270
PMCPMC10710914

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.